Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
Aileron Therapeutics (Nasdaq: ALRN) has announced data from its Phase 1b study of ALRN-6924, which aims to prevent chemotherapy-induced side effects in patients with p53-mutated small cell lung cancer (SCLC). The therapy utilizes a novel biomarker strategy to protect healthy cells while allowing chemotherapy to target cancer cells. A late-breaking poster presentation of the study will occur at the ENA 2020 Symposium. Aileron aims to expand chemoprotection across multiple cancer types, and an investor call is scheduled for October 26, 2020, to discuss the findings and future strategies.
- ALRN-6924 is the first chemoprotective therapy targeting p53-mutated cancers, addressing a significant unmet need.
- The therapy selectively shields healthy cells from chemotherapy, potentially improving patient quality of life.
- Positive interim data from the Phase 1b study supports further clinical development.
- None.
- Aileron aims to create new paradigm of proactive prevention of chemotherapy-induced side effects to address significant unmet need among cancer patients
- ALRN-6924 is first and only chemoprotective therapy in clinical development to utilize a biomarker strategy by treating patients with p53-mutated cancers
- Novel mechanism of action activates wild-type p53 to selectively shield healthy cells from chemotherapy without interrupting chemotherapy’s targeting of cancer cells
- Company to hold investor call on Monday, October 26, 2020 to discuss the new data and outline strategy to advance chemoprotection across multiple cancers and chemotherapies
WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020.
The abstract entitled, “Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDM2/MDMX inhibitor ALRN-6924,” (LBA96) will be presented starting Saturday, October 24, on the ENA 2020 website.
The data to be presented is from Aileron’s Phase 1b study, which is evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced toxicities, such as severe anemia, neutropenia and thrombocytopenia, in patients with p53-mutated small cell lung cancer (SCLC) who are being treated with the chemotherapy topotecan. In June 2020, Aileron announced positive interim data from this study.
“Chemotherapy, which remains the backbone of treatment for millions of cancer patients, is associated with toxicities and side effects – ranging from unpleasant to life-threatening, and sometimes fatal. Current supportive care drugs try to manage these side effects, but often unsuccessfully and with associated toxicities of their own. Aileron has the potential to bring much-needed innovation to this area of cancer care, improving patients’ quality of life as well as their tolerance for chemotherapy,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron Therapeutics.
Dr. Aivado continued, “ALRN-6924 is the first and only chemoprotective agent to utilize a biomarker strategy by treating patients with p53-mutated cancers. In these patients, ALRN-6924 is designed to selectively shield healthy non-p53-mutated cells while chemotherapy can continue targeting p53-mutated cancer cells. We believe that our novel mechanism of action has the potential to introduce a transformative paradigm of proactive prevention of hematological and non-hematological chemotherapy-induced side effects. Importantly, our approach is designed to give oncologists access to a chemoprotective agent that will not reduce the efficacy of chemotherapy.”
Aileron’s long-term vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent at least
Aileron Investor Call
Aileron will host a virtual investor call and webcast to discuss the new data as well as the company’s clinical development strategy to expand chemoprotection to patients with p53-mutated cancers. The event will take place on Monday, October 26 at 8:30 a.m. ET. Details will be provided closer to the event at https://investors.aileronrx.com/events-presentations/investor-events.
How ALRN-6924 Works to Protect Healthy Cells from Chemotherapy
ALRN-6924 is being developed by Aileron as a novel chemoprotective medicine to selectively protect healthy cells in patients with cancers that harbor p53-mutations to reduce or eliminate chemotherapy-induced side effects.
Chemotherapy preferentially acts on cells that are cycling, or undergoing the process of cell division. In cancer cells, the cell cycle is unchecked, which leads to uncontrolled cell proliferation, a hallmark of cancer. Certain types of healthy cells also naturally need to cycle, such as bone marrow cells, hair follicle cells, skin cells, and cells lining the oral cavity and the gastrointestinal tract. As a result, chemotherapy targets and kills both cycling healthy cells and cycling cancer cells. This, in turn, leads to a spectrum of chemotherapy-induced side effects, from unpleasant to life-threatening and fatal.
ALRN-6924, an investigational first-in-class MDM2/MDMX dual inhibitor, is administered prior to chemotherapy to patients with p53-mutant cancers. ALRN-6924 is designed to activate normal p53 protein in patients’ healthy cells, temporarily and reversibly pausing cell cycling to selectively shield the patients’ healthy cells from chemotherapy. The protection is limited to healthy cells, as ALRN-6924 cannot work in p53-mutated cancer cells given that p53 has lost its function in those cells. Therefore, cancer cells continue to cycle uninterrupted and remain fully susceptible to destruction by chemotherapy.
About Aileron Therapeutics
At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor activating p53, is the only therapeutic agent in development to employ a biomarker strategy to elicit selective chemoprotection for cancer patients. With this unique, targeted strategy, ALRN-6924 is designed to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.
In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients’ quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to bring chemoprotection to patients with p53-mutated cancers – approximately
Forward-Looking Statements
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the period ended June 30, 2020, filed on August 5, 2020, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.
| Investor Contacts: | Media Contact: |
| Richard Wanstall, SVP Chief Financial Officer | Liz Melone |
| Aileron Therapeutics | 617-256-6622 |
| 617-995-2822 | lmelone@aileronrx.com |
| rwanstall@aileronrx.com | |
| Hans C. Vitzthum | |
| LifeSci Advisors, LLC. | |
| 617-430-7578 | |
| hans@lifesciadvisors.com |
FAQ
What is ALRN-6924?
What were the results of the Phase 1b study of ALRN-6924?
When will the data for ALRN-6924 be presented?
What is the significance of ALRN-6924's biomarker strategy?
When will Aileron hold its investor call?
